Key result
Inoculation with formalin-treated serum containing a non-A, non-B hepatitis agent did not cause hepatitis in infant chimpanzees over 7 months of observation.
Why the study?
Does formalin treatment inactivate the agent of human non-A, non-B hepatitis in a chimpanzee model?
Population
4 colony-born infant chimpanzees
Comparison
Inoculation with serum containing human non-A… vs Uninoculated control chimpanzee
Design
Preclinical
Follow-up
7 months (initial observation), 31 weeks (challenge)
Authors
Loading...
Hypothesis-generating for formalin-inactivated non-A, non-B hepatitis prevention without immunity; human studies needed before any clinical translation.
Does formalin treatment inactivate the agent of human non-A, non-B hepatitis in a chimpanzee model?
Absolute Event Rate: 0% vs 0%
Formalin treatment effectively inactivates the agent of human non-A, non-B hepatitis without conferring immunity, as demonstrated in a chimpanzee model.
Tabor et al. (1980) studied Non-A, non-B hepatitis (n=4). Formalin-treated serum containing non-A, non-B hepatitis agent vs. Uninoculated control was evaluated on Development of recognizable non-A, non-B hepatitis. Inoculation with formalin-treated serum containing a non-A, non-B hepatitis agent did not cause hepatitis in infant chimpanzees over 7 months of observation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: